Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments Mar 23, 2023
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials Feb 27, 2023
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin Feb 14, 2023
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT Jan 26, 2023
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 Jan 18, 2023
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration Dec 12, 2022
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments Nov 10, 2022
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 Oct 27, 2022
